Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

Teo_j Sep. 9 at 10:55 AM

$PHIO

0 · Reply

Alidrisi Sep. 9 at 2:36 AM

$PHIO

0 · Reply

Telos52 Sep. 9 at 2:06 AM

$PHIO

0 · Reply

BrocM Sep. 8 at 8:35 PM

$OCTO If you got caught here or missed the run, don't worry! You can still catch $PHIO, it will do the same move as OCTO in the next few months but the difference will be that PHIO will keep it's gains due to its INTASYL product being a legit value added to the world. All you have to do is buy and hold until Cohort 5 results are announced, and profit. GLTA

0 · Reply

BrocM Sep. 8 at 8:26 PM

$OCTO Called it, easy read. $PHIO is the true king 🔥

1 · Reply

PitaPierogi Sep. 8 at 8:18 PM

$OCTO $PHIO big time runner! Phio! Bbbbbbbuyyyy OUTTT

0 · Reply

BrocM Sep. 8 at 7:43 PM

$OCTO Don't get caught here, this is done and going back under 10 dollars. May as well get in on the next run early. Next +5000% runner will be $PHIO

1 · Reply

BrocM Sep. 8 at 7:27 PM

$PHIO Did algos hit the reverse on this ticker today? Feels like it. INB4 200$ per share. $OCTO $UPC $QS

0 · Reply

BrocM Sep. 8 at 3:43 PM

$PHIO watch PHIO take off just like $OCTO when the 5th cohort results are out. Check out their HC wainwright presentation on sep 10. And this article will tell you why PHIO is the next OCTO: https://beyondspx.com/quote/PHIO/analysis/phio-pharmaceuticals-intasyl-s-precision-strike-in-immuno-oncology-nasdaq-phio

0 · Reply

BrocM Sep. 8 at 2:57 PM

$PHIO BOOOOM 💥💰🤑🚀

1 · Reply

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 25 days ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 6 weeks ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 6 weeks ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 6 weeks ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 4 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 5 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 6 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 6 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 7 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 8 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 8 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 8 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 8 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 8 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 9 months ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 9 months ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 9 months ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 10 months ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 10 months ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 11 months ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 11 months ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Chief Financial Officer

Jul 12, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Jul 8, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762

Jul 5, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Jul 2, 2024, 11:45 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Reverse Stock Split

Jun 18, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging

May 28, 2024, 7:30 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762

May 23, 2024, 5:00 PM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

Teo_j Sep. 9 at 10:55 AM

$PHIO

0 · Reply

Alidrisi Sep. 9 at 2:36 AM

$PHIO

0 · Reply

Telos52 Sep. 9 at 2:06 AM

$PHIO

0 · Reply

BrocM Sep. 8 at 8:35 PM

0 · Reply

BrocM Sep. 8 at 8:26 PM

$OCTO Called it, easy read. $PHIO is the true king 🔥

1 · Reply

PitaPierogi Sep. 8 at 8:18 PM

$OCTO $PHIO big time runner! Phio! Bbbbbbbuyyyy OUTTT

0 · Reply

BrocM Sep. 8 at 7:43 PM

$OCTO Don't get caught here, this is done and going back under 10 dollars. May as well get in on the next run early. Next +5000% runner will be $PHIO

1 · Reply

BrocM Sep. 8 at 7:27 PM

$PHIO Did algos hit the reverse on this ticker today? Feels like it. INB4 200$ per share. $OCTO $UPC $QS

0 · Reply

BrocM Sep. 8 at 3:43 PM

0 · Reply

BrocM Sep. 8 at 2:57 PM

$PHIO BOOOOM 💥💰🤑🚀

1 · Reply

PitaPierogi Sep. 8 at 12:14 PM

$OCTO WOOO! SHORTS ARE COOKED! NOW WE WAIT FOR $PHIO TO REIGN SUPREME ON THE DAILY GAINS!

0 · Reply

NVDAMillionaire Sep. 8 at 8:47 AM

$PHIO Excellent article that nails exactly where PHIO stands right now. So if you want to update your PHIO knowledge or get acquainted with PHIO, this is a must read. https://beyondspx.com/quote/PHIO/analysis/phio-pharmaceuticals-intasyl-s-precision-strike-in-immuno-oncology-nasdaq-phio

3 · Reply

Telos52 Sep. 5 at 7:42 PM

$PHIO

0 · Reply

Bartakhh Sep. 5 at 6:14 AM

$PHIO

0 · Reply

MerlinSbeard_ Sep. 4 at 3:09 PM

$PHIO

0 · Reply

DERDER Sep. 3 at 8:08 PM

$PHIO u have no clue!

1 · Reply

Teo_j Sep. 3 at 5:51 PM

$PHIO pure garbage

1 · Reply

PitaPierogi Sep. 3 at 12:31 PM

$PHIO boom new 8k. Phio Pharmaceuticals (NASDAQ: PHIO) Update: 🔹 Phio will present at the 27th Annual H.C. Wainwright Global Investment Conference on Sept 10, 2025 @ 1:30–2:00 PM EST in NYC. 🔹 CEO Robert Bitterman will provide updates on the PH-762 Phase 1b trial for skin cancer. 🔹 5th and likely final cohort now being treated. PH-762 targets PD-1 via their INTASYL® siRNA platform as a potential non-surgical skin cancer treatment. 🔬 Advancing in cutaneous squamous cell carcinoma, melanoma & Merkel cell carcinoma. 📅 1-on-1 investor meetings: Sept 8–10 📧 Contact: [email protected] 🌐 www.phiopharma.com

0 · Reply

coldfacts Sep. 3 at 12:06 PM

$PHIO seems like they’re going to sell the news

1 · Reply

PitaPierogi Sep. 3 at 11:52 AM

$PHIO WE WILL BE AT 14!

0 · Reply

ACInvestorBlog Sep. 3 at 11:46 AM

$PHIO Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-762 Presentation Details: September 10, 2025 at 1:30-2 PM EST Location: 27th Annual H.C. Wainwright Global Investment Conference, Lotte New York Plaza Hotel, New York City, NY

0 · Reply

newsfile_corp Sep. 3 at 11:45 AM

https://nfne.ws/264836 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

Market Cap	11.68M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	128,100
Avg Vol	1,150,944
Day's Range	N/A - N/A
Shares Out	5.73M
Stochastic %K	84%
Beta	0.89
Analysts	Sell
Price Target	$14.00